Lansoprazole
- Generic Name
- Lansoprazole
- Brand Names
- Prevacid, Prevpac
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N3O2S
- CAS Number
- 103577-45-3
- Unique Ingredient Identifier
- 0K5C5T2QPG
- Background
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.
- Indication
Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis. Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy).
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis
Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Far Eastern Memorial Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT00708149
- Locations
- 🇨🇳
Far Eastern Memorial Hospital, Taipei, Taiwan
Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 852
- Registration Number
- NCT00701259
- Locations
- 🇺🇸
Not applicable - enrollment complete, Parsippany, New Jersey, United States
Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain
- Conditions
- Pain, Fracture, Sprain
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00685295
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Lansoprazole Versus Mosapride for Functional Dyspepsia
- Conditions
- Functional DyspepsiaEpigastric Pain SyndromePost Prandial Distress Syndrome
- Interventions
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2009-10-09
- Lead Sponsor
- Lotung Poh-Ai Hospital
- Target Recruit Count
- 329
- Registration Number
- NCT00663897
- Locations
- 🇨🇳
Lotung Poh-Ai hospital, Lotung Town, Ilan county, Taiwan
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT00644735
A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00641602
Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)
- Conditions
- HeartburnGastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 248
- Registration Number
- NCT00637845
Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT00637416
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients
- Conditions
- HeartburnUpper Abdominal PainNauseaAcid Regurgitation
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2008-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00625274
Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD
- Conditions
- Gastroesophageal RefluxGERD
- Interventions
- Procedure: Antireflux surgery
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 24
- Registration Number
- NCT00624546
- Locations
- 🇺🇸
Strong Memorial Hospital, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.